NCT06534944View on ClinicalTrials.gov

NAD Supplementation and Vascular Health in PAD

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

July 30, 2024

Study Completion Date

December 30, 2024

Conditions
Peripheral Artery Disease
Interventions
DRUG

Nicotinamide riboside

NR 1g daily for 4 weeks

Trial Locations (1)

73104

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER